Jean-Charles Soria, SVP and Oncology Therapeutic Area Head at Amgen, shared a post on LinkedIn:
“Lung cancer in never smokers: actionable implications for practice:
- Driver-rich biology: 78–92% actionable (EGFR/ALK); low TMB – limited ICI benefit – perform broad NGS upfront.
- Etiology: germline risk (EGFR T790M, APOBEC3A/B), CHIP-driven inflammation, radon, second-hand smoke (~20–25% ↑ risk), PM2.5. (air pollution)
- Screening: LDCT benefit proven in smokers; in never-smokers, consider only high-risk subgroups (e.g., family history).
- Adjuvant precision: EGFR TKIs improve outcomes post-resection-test early-stage disease.
- Prevention horizon: IL-1β targeting and neoantigen vaccines under investigation.”
Title: Lung cancer in never smokers: from early detection to prevention
Authors: Deborah Caswell, Crispin Hiley, Cian Murphy, Loc Carlo Bao, Charles Swanton
Read the Full Article.
Other articles featuring Jean-Charles Soria.